By Staff writer
Gilead Sciences said more supply will become available in July
United Arab Emirates’ Ministry of Health and Prevention has granted regulatory approval to Gilead Sciences for remdesivir, the first drug shown to be relatively effective in treating Covid-19.
At least two major US studies have shown that the anti-viral drug can reduce the duration of hospital stays for those suffering from the novel coronavirus.
While there is currently limited global supply of remdesivir, Gilead said it anticipates new supply of the drug will start to become available in July, with supply continuing to increase through the end of this year and into next year.
Gilead said will work closely with the health authorities in UAE to provide guidance on anticipated drug supply based on local incidence and severity of disease.
The US government announced last week that it had bought 92 percent of all remdesivir production by the Gilead laboratory until the end of September - about 500,000 treatments out of nearly 550,000. Each treatment requires 6.25 vials on average.